GlassScriptPhysician profile
Christine Marie Danforth
NPI 1679665558
$5,371.79
in general payments reported to CMS, 2019-2025
35 companies · $62.72 in 2025
The $62.72 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $1,352 · 2021: $1,328 · 2022: $1,711 · 2023: $104 · 2024: $49.34 · 2025: $62.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $215.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $764.11 | 2019-2022 | |
| Novo Nordisk INC | $670.52 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $610.28 | 2019-2023 | Breztri |
| Abbvie INC. | $601.23 | 2019-2023 | Ubrelvy |
| Amgen INC. | $420.39 | 2019-2023 | Otezla, Repatha |
| Allergan, INC. | $328.69 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $243.75 | 2020-2022 | |
| Glaxosmithkline, LLC. | $185.31 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.28 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.26 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.45 | 2019-2023 | Xifaxan, Trulance |
| Mylan Specialty L.P. | $111.38 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.82 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $96.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.74 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $86.86 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $71.61 | 2022-2025 | Qelbree |
| Dexcom, INC. | $57.75 | 2021-2022 | |
| Eisai INC. | $49.36 | 2020 | |
| Astellas Pharma US INC | $48.75 | 2023-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $47.47 | 2020 | |
| Esperion Therapeutics, INC. | $39.55 | 2021 | |
| Genentech USA, INC. | $31.88 | 2019-2021 | |
| Abbott Laboratories | $30.35 | 2022 | |
| Avanir Pharmaceuticals, INC. | $29.86 | 2021 | |
| Sunovion Pharmaceuticals INC. | $28.66 | 2021 | |
| Shield Therapeutics INC | $22.58 | 2022 | |
| Biotronik Nro, INC. | $22.11 | 2025 | Prospera |
| Idorsia Pharmaceuticals US INC | $18.49 | 2022 | |
| Almatica Pharma LLC | $17.04 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.34 | 2022 | |
| Bausch Health US, LLC | $15.87 | 2021 | |
| Corcept Therapeutics | $15.79 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $13.13 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Danforth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.